| 沙利度胺的最新研究进展 |
| |
| 引用本文： | 臧洪梅,周建平,吕慧侠. 沙利度胺的最新研究进展[J]. 药学进展, 2008, 32(1): 21-27 |
| |
| 作者姓名： | 臧洪梅 周建平 吕慧侠 |
| |
| 作者单位： | 中国药科大学药剂学教研室,江苏,南京,210009 |
| |
| 摘 要： | 沙利度胺因致畸作用撤出市场后又被发现在抗炎及免疫调节方面具有活性，并被美国FDA批准用于治疗麻风并发症麻风结节性红斑。近年来其抗血管生成的作用又成为研究热点，2006年5月美国FDA批准其用于治疗多发性骨髓瘤，该药再次受到医学界的瞩目。综述近年来在沙利度胺的抗肿瘤作用机制、现有和潜在的临床疗效以及制剂学等方面的研究进展。
|
| 关 键 词： | 沙利度胺 多发性骨髓瘤 抗血管生成 |
| 文章编号： | 1001-5094（2008）01-0021-07 |
| 收稿时间： | 2007-10-24 |
| 修稿时间： | 2007-10-24 |
Current Progress in Research on Thalidomide |
| |
| ZANG Hong-mei,ZHOU Jian-ping,Lü Hui-xia. Current Progress in Research on Thalidomide[J]. Progress in Pharmaceutical Sciences, 2008, 32(1): 21-27 |
| |
| Authors: | ZANG Hong-mei ZHOU Jian-ping Lü Hui-xia |
| |
| Affiliation: | ZANG Hong-mei, ZH0U Jian-ping, Lü Hui-xia ( Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ) |
| |
| Abstract: | Although thalidomide was withdrawn from the European markets because of its teratogenic potential, FDA approved it for erythema nodosum leprosum lesions in 1998. And again thalidomide was approved for the treatment of multiple myeloma owing to its anti-vascularization at May of 2006. The current progress in research on thalidomide was summarized, including its mechanism of anti-tumor, curative effect and pharmaceutics. |
| |
| Keywords: | Thalidomide Multiple myeloma Anti-vascularization |
| 本文献已被 维普 万方数据 等数据库收录！ |
